# Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer

> **NCT05014776** · PHASE2 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 17 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Tadalafil
- **DRUG:** Pembrolizumab
- **DRUG:** Ipilimumab
- **DRUG:** CRS-207

## Key facts

- **NCT ID:** NCT05014776
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-22
- **Primary completion:** 2024-04-03
- **Final completion:** 2025-06-19
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2026-04-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05014776

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05014776, "Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05014776. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*